All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
Pediatric patients with hematological malignancies are commonly treated with busulfan- or fractionated total body irradiation (TBI)-based myeloablative conditioning regimens prior to allogenic hematopoietic stem cell transplantation (allo-HSCT). However, both these treatment options are associated with an increased risk of adverse events (AEs). Treosulfan-based conditioning prior to allo-HSCT has been shown to have myeloablative, immunosuppressive, and antineoplastic effects that are associated with a reduced risk of non-relapse mortality (NRM) in adult patients with AML and MDS. Therefore, Krzysztof Kalwak et al. published results of a phase II, non-randomized, prospective study that evaluated the safety and efficacy of treosulfan/fludarabine conditioning in children in Bone Marrow Transplantation.1
Clinical endpoint
Treatment and dosing
Table 1. Patient characteristics and transplant data by hematological malignancy1
|
Disease |
||||
---|---|---|---|---|---|
ALL (N = 23) |
AML (N = 29) |
MDS (N = 10) |
JMML (N = 3) |
Overall (N = 65) |
|
Age [years] |
|||||
Median |
12.0 |
8.0 |
14.0 |
2.0 |
11.0 |
ICH age group [n (%)] |
|||||
28 days to 23 months |
2 (8.7%) |
4 (13.8%) |
1 (10.0%) |
1 (33.3%) |
8 (12.3%) |
2–11 years |
7 (30.4%) |
14 (48.3%) |
2 (20.0%) |
2 (66.7%) |
25 (38.5%) |
12–17 years |
14 (60.9%) |
11 (37.9%) |
7 (70.0%) |
0 (0.0%) |
32 (49.2%) |
Number of HSCT [n (%)] |
|||||
First |
22 (95.7%) |
28 (96.6%) |
8 (80.0%) |
2 (66.7%) |
60 (92.3%) |
Second |
1 (4.3%) |
1 (3.4%) |
2 (20.0%) |
1 (33.3%) |
5 (7.7%) |
Treosulfan dose [n (%)] |
|||||
10 g/m2/day −6, −5, −4 |
1 (4.3%) |
3 (10.3%) |
0 (0.0%) |
1 (33.3%) |
5 (7.7%) |
12 g/m2/day −6, −5, −4 |
5 (21.7%) |
13 (44.8%) |
3 (30.0%) |
2 (66.7%) |
23 (35.4%) |
14 g/m2/day −6, −5, −4 |
17 (73.9%) |
13 (44.8%) |
7 (70.0%) |
0 (0.0%) |
37 (56.9%) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ICH, International Council of Harmonization; JMML, juvenile myelomonocytic leukemias; MDS, myelodysplastic syndrome; N/A, not applicable
aFor ALL and AML subjects only.
Engraftment and chimerism
NRM and RI incidence
RFS/PFS
GvHD
GRFS and CRFS
OS
Safety
Pharmacokinetics
The treosulfan/fludarabine/thiotepa conditioning regimen with BSA-adapted dosing was deemed tolerable and efficacious in children with hematological malignancies. The cumulative incidences of OS and NRM compared well to other conditioning regimens. However, a limitation of this study is the small sample size of patients treated, particularly in the MDS and JMML subgroups. Therefore, the poor outcome shown for patients with JMML should be interpreted with caution. Based on recent clinical data, the European Commission has approved treosulfan in combination with fludarabine as part of conditioning treatment prior to allo-SCT in children older than 1 month with malignant diseases. This study provides further confirmation of the myeloablative potential of the treosulfan/fludarabine/thiotepa conditioning regimen, which induced a good rate of complete donor-type chimerism.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content